Although several FAK inhibitors, such as Defactinib, have shown promise and are undergoing clinical evaluation, including receiving FDA Fast Track designation for combination therapy in mesothelioma (25), no FAK-targeting small molecule has yet received full regulatory approval for standard clinical use. The gene discussed is PTK2; the disease is mesothelioma.